Aberrant activations of Fms-like tyrosine receptor kinase (FLT) 3 are implicated in the
pathogenesis of 20% to 30% of patients with acute myeloid leukemia (AML). G-749 is a …

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30%
of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure …

More than one-third of patients with acute myeloid leukemia (AML) harbor aberrant
mutations in Fms-like tyrosine kinase 3 (FLT3). Among them, the internal tandem duplication …

FLT3 mutations are the most frequently identified genetic alterations in acute myeloid
leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in …

Tyrosine kinase domain (TKD) mutations contribute to acquired resistance to FMS-like
tyrosine kinase 3 (FLT3) inhibitors used to treat FLT3-mutant acute myeloid leukemia (AML) …

There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3
(FLT3) tyrosine kinase inhibitors (TKI) in patients with acute myeloid leukemia (AML) …

Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the
treatment of FLT3-ITD+ acute myeloid leukaemia (AML). The paucity of valid pre-clinical …

Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with
FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance …

Abstract Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells
of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target …

An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which
is expressed in a subpopulation of patients with acute myelocyic leukemia (AML) and is …